Advances in the Development and Application of Targeted Radiopharmaceuticals for Cancer Management, 2nd Edition
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (31 August 2023) | Viewed by 5040
Special Issue Editor
Interests: breast cancer; prostate cancer; nuclear imaging and therapy; targeted therapy; molecular and cell biology; cancer diagnostics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In the past decades, the development and application of targeted radiopharmaceuticals for the imaging and treatment of cancer have been an emerging area of research, not only in the field of nuclear medicine but also in that of cancer research in general. In the late 1980s–early 1990s, the first successful preclinical and clinical studies were performed with a targeted radiopharmaceutical. Following this success, a broad range of targeted radiopharmaceuticals directed against different cancer types have been developed. Over time, many research breakthroughs occurred, which led to the improvement of targeted radiopharmaceuticals and their application. As a result of these breakthroughs, a radiopharmaceutical was recently EMA- and FDA-approved for the treatment of neuroendocrine tumours. Despite the major advances in the development of radiopharmaceuticals that have been made over the years, there is still room for improvement. This Special Issue of Pharmaceutics will focus on novel advances in the development of radiopharmaceuticals for cancer imaging and therapy. This includes, but is not limited to, studies on the production and use of novel radionuclides, the development and application of new radiotracers, and the application of advanced strategies to improve radiopharmaceuticals’ pharmacokinetics. Short communications, original research papers, and reviews are welcome.
Dr. Simone U. Dalm
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- radiopharmaceuticals
- theranostics
- imaging
- treatment
- radionuclides
- cancer
- radiochemistry
- dosimetry
- in vitro and in vivo studies
- clinical studies
- molecular biology
- safety
- toxicity
